Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Free Dating
Ñompany Maksim-LLC. Ýëåêòðîïðèâîäû. Made and sell. אחסנה
Popular Articles

Global Fund Faces $3B Funding Shortfall
The Global Fund to Fight AIDS, Tuberculosis and Malaria is facing a budget shortfall of about $3 billion, Marcela Rojo, a Global Fund spokesperson, said on Friday, Reuters reports. Rojo said the Global Fund needs $170 million to pay for the programs it committed to supporting last year, and the organization will need between $2.5 billion and $3 billion to maintain and finance programs planned for 2010. "The Global Fund will need a substantially higher amount than the one pledged at the last replenishment in Berlin in 2007 ($10 billion)," Rojo said, adding, "The decisions that are made in the next 18 months will be critical for sustaining the gains achieved in global health so far and further scaling up programmes."
new payday loan lenders flonase online
NARAL Endorses Sen. Gillibrand's 2010 Bid For Full Senate Term
NARAL Pro-Choice America on Monday announced its endorsement of appointed Sen. Kirsten Gillibrand (D-N.Y.) in her bid for a full term in 2010, Politico reports. New York Gov. David Paterson (D) in January appointed Gillibrand to fill the Senate seat vacated by U.S. Secretary of State Hillary Rodham Clinton.NARAL"s political action committee to date has contributed $5,000 to Gillibrand"s campaign, and it plans to organize its more than 63,000 members on her behalf, according a press release from the group. The release calls Gillibrand "a rising star among pro-choice leaders in the Senate." It adds, "She is a resilient campaigner whose fully pro-choice voting record reflects an unwavering commitment to the values of freedom and privacy." NARAL endorsed Gillibrand in her successful 2006 and 2008 House election campaigns (Abrahamson, Politico, 6/30).
pdf password remover mac
News of the day
Revealing Leukemia-Initiating Cells
Two new studies reveal a way to increase the body"s appetite for gobbling up the cancer stem cells responsible for acute myeloid leukemia (AML), a form of cancer with a particularly poor survival rate. The key is targeting a protein on the surface of those cells that sends a "don"t eat me" signal to the macrophage immune cells that serve as a first line of defense, according to the reports in the July 24th issue of the journal Cell, a Cell Press publication.
Oncology

The Integration Of The Nellcor™ OxiMax™ SpO2 System Into Philips Patient Monitors Announced By Covidien

Covidien (NYSE: COV), a leading global supplier of healthcare products, has announced the integration of its Nellcor™ OxiMax™ oximetry system into Philips IntelliVue and M-Series patient monitors. Philips is a leading global provider of patient monitoring solutions, and the collaboration between the companies is expected to significantly increase, in all major geographies, hospitals" and healthcare providers" access to the industry-leading capabilities offered by both companies. Customers will have the added flexibility of choosing the Nellcor OxiMax technology in Philips IntelliVue and M-Series patient monitors for critical care areas such as the Intensive Care, Emergency, Anesthesia and Neonatal Care departments. This enables the IntelliVue and M-Series patient monitors to be compatible with Covidien"s Nellcor OxiMax specialty sensors, including the Max-Fast™ forehead sensor for patients with poor perfusion and the SoftCare™ nonadhesive sensor line for patients with sensitive skin, including newborns. In the intensive care unit and other high-acuity areas of the hospital, Max-Fast and SoftCare sensors support effective, comfortable care for the most critical patients. "Hospitals and clinicians are under constant pressure to improve outcomes and decrease costs. In turn, they are demanding expanded access to the technologies and medical devices they trust," said Chris Lowery, General Manager and Vice President, Patient Monitoring, Covidien. "Covidien"s partnership with Philips gives hospitals access to advanced technology from two leading medical monitoring companies. The successful completion of this collaboration with Philips, a recognized industry leader in patient monitoring, is consistent with Covidien"s mission to provide products that help clinicians deliver safe and efficacious patient care, while simultaneously maximizing hospital efficiency." "Many clinicians have expressed great interest in Nellcor OxiMax technology in our IntelliVue patient monitors," said David Russell, Vice President and Chief Marketing Officer, Informatics and Patient Monitoring, Philips Healthcare. "This collaboration enhances our ability to provide customers in the USA, Europe and many other markets with a choice of their preferred trusted pulse oximetry technology. This partnership also underscores Philips" commitment to providing clear, accurate information to support clinical decision-making across all areas of the hospital." Katherine Tripple Feinstein Kean Healthcare


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009